Vittamed secures $10M in venture funding for commercialization of non-invasive Intracranial Pressure (ICP) system

BOSTONOct. 16, 2015 /PRNewswire/ — Vittamed Corporation, a neurodiagnostic company that has developed a novel non-invasive intracranial pressure monitor announced that it has secured $10M in Series A financing by Xeraya Capital Labuan Ltd (“Xeraya Capital”) via a special purpose vehicle led the investment round (committed $8M) with additional commitment from an existing investor Imprimatur Capital and other investors. The funding will support product launch in Europe, Australia, and other countries, a 510k submission to the FDA, and commercialization in the US.

Full Text: PRNewswire

2017-12-12T18:43:38+00:00